Business
Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021
Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February...
About this update from Medicure Inc.
[{"type":"text","content":"\n \n \n \n Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n WINNIPEG, MB,\n \n Feb. 4, 2021\n \n /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on\n \n Monday, February 8, 2021\n \n at\n \n 2:00 PM EST\n \n (\n \n 1:00 PM CST\n \n ,\n \n 12:00 PM MST\n \n ). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.\n \n \n The presentation will feature\n \n Albert Friesen\n \n , Chief Executive Officer & Chairman of the Board. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company's website (\n \n www.medicure.com\n \n ).\n \n \n REGISTER HERE:\n \n \n \n https://talk-deck.com/info/live-register/?297!ut9dx30v1dy\n \n \n \n \n \n \n \n To ensure smooth connectivity, please access this link using the latest version of Google Chrome.\n \n \n \n \n \n \n About Medicure Inc.\n \n \n \n \n Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in\n \n the United States\n \n , where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (\"Marley\"), a pharmacy located in\n \n North Carolina\n \n that offers an Extended Supply mail order drug program serving all 50 states,\n \n Washington D.C.\n \n and\n \n Puerto Rico\n...